Deleted Tweets From Scott Gottlieb, R-D.C.

RT @HHSGov: #HappeningTomorrow Inaugural meeting of the Pain Management Best Practices Inter-Agency Task Force https://t.co/63uKpuDgic QT @HHS_ASH: Pain is REAL and those who suffer from pain should not be forgotten during our efforts to combat the opioid epidemi… https://t.co/FhPs9BeyQZ)

RT @CDCgov: Parents: make sure your preteen or teen is up to date with #meningococcal vaccination. https://t.co/cO5iZevQVl… https://t.co/l5N7Yd6Cnv

#FDA takes new steps to advance digital health https://t.co/dxeUHYgqW9

As part of ongoing efforts to combat opioid crisis, #FDA is launching an innovation challenge to spur development of medical devices ‒ including digital health technologies and diagnostic tests ‒ that target pain, addiction and diversion: https://t.co/2vY

#FDA will accept submissions from June 1 through Sept. 30 and intends to announce selected applicants in November. Selected companies will be provided an opportunity to work closely with #FDA to accelerate development & review of their innovative prod

The comments we’re asking for on software device functions that aren’t subject to FDA regulation will be used to inform our future policymaking and a report to Congress later this year:  https://t.co/dxeUHYgqW9

Medical devices have the potential to play a unique and important role in tackling the opioid crisis by providing novel solutions to detecting, treating and preventing addiction, addressing diversion and treating pain: https://t.co/2vYePOcRNV

This new innovation challenge is part of #FDA’s commitment to an all-of-the-above approach to confront the opioid epidemic, including helping those currently addicted to opioids and preventing new cases of addiction: https://t.co/2vYePOcRNV

We’re hopeful that in collaborating with public health-minded innovators, we can identify and accelerate the development of new technologies that can contribute in novel and effective ways to help reduce the scope of the opioid crisis: https://t.co/2vYePO

#FDA issued a draft guidance today encouraging companies to use innovative manufacturing tech and processes, making it easier for them to manage post-approval changes across different global markets by reducing unnecessary regulatory burdens and costs. ht

My statement today on federal preparedness and #FDA’s response efforts to the #Ebola virus outbreak in the Democratic Republic of Congo (DRC): https://t.co/nAXJ2o5SVO https://t.co/omKvO4lhAq

This streamlined, harmonized approach laid out in today’s draft guidance on innovative manufacturing tech will promote continual product improvement and a more stable supply chain to ensure patients have access to the drug products they need. https://t.co

RT @FDA_Drug_Info: #FDA releases new Draft Guidance – Assessment of Pressor Effects of Drugs to advise sponsors on the premarketing as… https://t.co/vV43lvaWVB

#FDA committed to facilitating development of investigational drugs for treatment of Ebola virus and supporting access to these products under appropriate regulatory pathways, helping assist sponsors make sure an adequate supply of treatments is available

FDA is committed to ensuring patients have access to safe and effective drug products without disruption. Innovations and improvements in manufacturing processes can help avoid drug shortages while ensuring it meets #FDA’s rigorous quality standards. http

My statement today on what #FDA is doing to mitigate shortages of intravenous drugs, shorten supply disruptions, and better predict vulnerabilities: https://t.co/a7HazbFVS9

RT @FDAJobs: Looking for a Regulatory Counsel position? The Office of Generic Drugs Policy is looking to fill many vacancies in… https://t.co/LhhzJOpi5s

#FDA is committed to investigating the E. coli outbreak linked to romaine. We issued a traceback diagram to show how several clusters of illnesses connect from points of service to many fields https://t.co/WPSRTbvM5S

The only point of commonality in our traceback efforts to date is that all farms are located in Yuma growing region. We’re actively evaluating a number of theories about how multiple farms in same growing region could have become contaminated to find root

RT @AlecGaffney: Interesting. FDA raises stakes for companies not implementing shared REMS system by allowing generic companies to petition… QT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on new policies to reduce the ability of brand drug makers to use REM… https://t.co/fhQtt1Ax7P)

RT @HHSGov: #HappeningTomorrow Inaugural meeting of the Pain Management Best Practices Inter-Agency Task Force https://t.co/63uKpuDgic QT @HHS_ASH: Pain is REAL and those who suffer from pain should not be forgotten during our efforts to combat the opioid epidemi… https://t.co/FhPs9BeyQZ)

RT @CDCgov: Parents: make sure your preteen or teen is up to date with #meningococcal vaccination. https://t.co/cO5iZevQVl… https://t.co/l5N7Yd6Cnv

#FDA takes new steps to advance digital health https://t.co/dxeUHYgqW9

As part of ongoing efforts to combat opioid crisis, #FDA is launching an innovation challenge to spur development of medical devices ‒ including digital health technologies and diagnostic tests ‒ that target pain, addiction and diversion: https://t.co/2vY

#FDA will accept submissions from June 1 through Sept. 30 and intends to announce selected applicants in November. Selected companies will be provided an opportunity to work closely with #FDA to accelerate development & review of their innovative prod

The comments we’re asking for on software device functions that aren’t subject to FDA regulation will be used to inform our future policymaking and a report to Congress later this year:  https://t.co/dxeUHYgqW9

Medical devices have the potential to play a unique and important role in tackling the opioid crisis by providing novel solutions to detecting, treating and preventing addiction, addressing diversion and treating pain: https://t.co/2vYePOcRNV

This new innovation challenge is part of #FDA’s commitment to an all-of-the-above approach to confront the opioid epidemic, including helping those currently addicted to opioids and preventing new cases of addiction: https://t.co/2vYePOcRNV

We’re hopeful that in collaborating with public health-minded innovators, we can identify and accelerate the development of new technologies that can contribute in novel and effective ways to help reduce the scope of the opioid crisis: https://t.co/2vYePO

#FDA issued a draft guidance today encouraging companies to use innovative manufacturing tech and processes, making it easier for them to manage post-approval changes across different global markets by reducing unnecessary regulatory burdens and costs. ht

My statement today on federal preparedness and #FDA’s response efforts to the #Ebola virus outbreak in the Democratic Republic of Congo (DRC): https://t.co/nAXJ2o5SVO https://t.co/omKvO4lhAq

This streamlined, harmonized approach laid out in today’s draft guidance on innovative manufacturing tech will promote continual product improvement and a more stable supply chain to ensure patients have access to the drug products they need. https://t.co

RT @FDA_Drug_Info: #FDA releases new Draft Guidance – Assessment of Pressor Effects of Drugs to advise sponsors on the premarketing as… https://t.co/vV43lvaWVB

#FDA committed to facilitating development of investigational drugs for treatment of Ebola virus and supporting access to these products under appropriate regulatory pathways, helping assist sponsors make sure an adequate supply of treatments is available

FDA is committed to ensuring patients have access to safe and effective drug products without disruption. Innovations and improvements in manufacturing processes can help avoid drug shortages while ensuring it meets #FDA’s rigorous quality standards. http

My statement today on what #FDA is doing to mitigate shortages of intravenous drugs, shorten supply disruptions, and better predict vulnerabilities: https://t.co/a7HazbFVS9

RT @FDAJobs: Looking for a Regulatory Counsel position? The Office of Generic Drugs Policy is looking to fill many vacancies in… https://t.co/LhhzJOpi5s

#FDA is committed to investigating the E. coli outbreak linked to romaine. We issued a traceback diagram to show how several clusters of illnesses connect from points of service to many fields https://t.co/WPSRTbvM5S

The only point of commonality in our traceback efforts to date is that all farms are located in Yuma growing region. We’re actively evaluating a number of theories about how multiple farms in same growing region could have become contaminated to find root

RT @AlecGaffney: Interesting. FDA raises stakes for companies not implementing shared REMS system by allowing generic companies to petition… QT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on new policies to reduce the ability of brand drug makers to use REM… https://t.co/fhQtt1Ax7P)